GlycoVaxyn's technology paves the way for synthesizing bioconjugate material to levels previously unattainable and in a more cost-effective manner.
|
GlycoVaxyn will be presenting at the VACCINE INNOVATION MEETING in Frankfurt, Germany on April 28-29, 2010 |